<DOC>
	<DOC>NCT02603926</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).</brief_summary>
	<brief_title>Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>Inclusion Criteria Fragile X premutation carrier status (55 to 200 CGG repeats in FMR1), Diagnosis of FXTAS including an intention tremor and/or ataxia and/or deficits on the BDS2 demonstrating executive function deficits. Exclusion Criteria other genetic problems in addition to the premutation a history of significant brain trauma significant substance abuse inability to follow the protocol liver or kidney disease heart failure active cancer other serious systemic disease current use of phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>